Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
As inflation persists, Baby Boomers are leveraging decades of financial experience to cut costs strategically. We examine the key spending categories they avoid and the generational mindset behind their money choices.
CNBC's Jim Cramer reaffirmed his bullish stance on Rio Tinto, highlighting the mining giant's role as a strategic hedge against geopolitical and economic volatility during the show's Lightning Round.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Despite modest nominal gains, real wages for U.S. workers are failing to keep pace with the cost of living, with a majority reporting financial strain as structural economic shifts and technological efficiencies redirect gains away from paychecks.
A 65-year-old Thai tourist was killed by a bull elephant with a known history of aggression in Khao Yai National Park, marking the animal's third human fatality and prompting urgent discussions on wildlife management strategies.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
Peoples Financial Services Corp. (PFIS) has announced that President Thomas P. Tulaney will retire in April 2026. CEO Gerard A. Chambi is expected to assume the president role, with Tulaney transitioning to a senior advisory position to ensure continuity.
A landmark all-stock merger between Devon Energy and Coterra Energy will create a $58 billion powerhouse, positioning it as a top-tier producer in the prolific Permian Basin amid a wave of industry consolidation.
The release of over three million documents by the U.S. Department of Justice has unveiled extensive communications between Jeffrey Epstein and a global network of powerful figures, raising fresh questions about influence, access, and accountability.
Russia's Foreign Ministry issued a stark warning on Monday, stating any deployment of foreign military forces or infrastructure in Ukraine would be considered an intervention, making those forces lawful targets for Russian strikes.
The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.
Elliot Staples III receives jail time after pleading guilty to manslaughter in the death of 3-year-old Jajuan Robinson, Jr., whom he was caring for when the child accessed an unsecured firearm.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
MTF Enterprises, a major operator of 43 Subway restaurants across four states, has filed for Chapter 11 bankruptcy, citing unsustainable debt burdens from merchant cash advance loans. The move highlights ongoing pressures within the franchise sector.
Investment firm Monument Capital Management has completely exited its position in Grand Canyon Education, selling 19,133 shares. The move comes as the education services provider navigates legal challenges and market underperformance.
